Laboratorios Farmaceuticos Rovi (MEX:ROVIN) Long-Term Debt: MXN0 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:ROVIN Laboratorios Farmaceuticos Rovi SA MEX:ROVIN
81 GF Score
Price MXN1,168.82
GF Value MXN1,103.32
! 2 Warning Signs
View Full Analysis

What is Laboratorios Farmaceuticos Rovi Long-Term Debt?

Laboratorios Farmaceuticos Rovi MEX:ROVIN 81 Long-Term Debt is MXN0 Mil as of Jun. 2026. GuruFocus rates MEX:ROVIN with a GF Score™ of 81/100 and a GF Value™ of MXN1,103.32. The stock has 2 warning signs investors should review.

Laboratorios Farmaceuticos Rovi's Long-Term Debt for the quarter that ended in Jun. 2026 was MXN0 Mil.

Laboratorios Farmaceuticos Rovi's quarterly Long-Term Debt declined from Dec. 2025 (MXN1,768 Mil) to Mar. 2026 (MXN0 Mil) but then stayed the same from Mar. 2026 (MXN0 Mil) to Jun. 2026 (MXN0 Mil).

Laboratorios Farmaceuticos Rovi's annual Long-Term Debt increased from Dec. 2023 (MXN714 Mil) to Dec. 2024 (MXN1,758 Mil) and increased from Dec. 2024 (MXN1,758 Mil) to Dec. 2025 (MXN1,768 Mil).

Laboratorios Farmaceuticos Rovi  (MEX:ROVIN) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Laboratorios Farmaceuticos Rovi Long-Term Debt Related Terms

Laboratorios Farmaceuticos Rovi Long-Term Debt Historical Data

* Premium members only.

The historical data trend for Laboratorios Farmaceuticos Rovi's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Laboratorios Farmaceuticos Rovi Long-Term Debt Chart

Laboratorios Farmaceuticos Rovi Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Long-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,217.47 950.93 714.05 1,758.06 1,768.44

Laboratorios Farmaceuticos Rovi Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 1,768.44 0.00 0.00
MEX:ROVIN
81GF Score
Laboratorios Farmaceuticos Rovi SA MEX:ROVIN
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of MXN0 Mil mean?
Laboratorios Farmaceuticos Rovi (MEX:ROVIN) has a Long-Term Debt of MXN0 Mil as of Jun. 2026.
Is Laboratorios Farmaceuticos Rovi's Long-Term Debt too high?
Laboratorios Farmaceuticos Rovi's current Long-Term Debt is MXN0 Mil. Overall, Laboratorios Farmaceuticos Rovi has a GF Score™ of 81/100, reflecting its overall financial health beyond just this single metric.
How does Laboratorios Farmaceuticos Rovi's Long-Term Debt compare to ZTS and UTHR?
Laboratorios Farmaceuticos Rovi's Long-Term Debt of MXN0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Drug Manufacturers company?
A good Long-Term Debt depends on the Drug Manufacturers industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. Laboratorios Farmaceuticos Rovi's current Long-Term Debt is MXN0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Laboratorios Farmaceuticos Rovi stock overvalued right now?
Laboratorios Farmaceuticos Rovi (MEX:ROVIN) has a current Long-Term Debt of MXN0 Mil. The stock's GF Value™ is MXN1,103.32, compared to a current price of MXN1,168.82 — trading 5.9% above its estimated fair value. The current Long-Term Debt is MXN0 Mil. Laboratorios Farmaceuticos Rovi's overall GF Score™ is 81/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For Laboratorios Farmaceuticos Rovi (MEX:ROVIN), the current Long-Term Debt is MXN0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Laboratorios Farmaceuticos Rovi (MEX:ROVIN) Overvalued in 2026?

Based on GuruFocus' analysis, Laboratorios Farmaceuticos Rovi stock appears to be overvalued. The current stock price of MXN1,168.82 is trading 5.9% above its estimated GF Value™ of MXN1,103.32.

Key valuation signals for MEX:ROVIN:

  • Long-Term Debt: MXN0 Mil
  • GF Value™: MXN1,103.32 vs. price of MXN1,168.82 (5.9% above fair value)
  • GF Score™: 81/100 with 2 warning signs

No single metric tells the full story. See the MEX:ROVIN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Laboratorios Farmaceuticos Rovi Business Description

Address Julian Camarillo, 35, Madrid, ESP, 28037
Laboratorios Farmaceuticos Rovi SA is a biotechnology company engaged in the research, development, manufacturing, and marketing of small molecule and specialty biologic drugs. The company has a diversified portfolio of products that it markets in Spain through its specialized sales force of specialist physicians, hospitals and pharmacies. Laboratorios' research and development pipeline is focused on the expansion of applications, indications, and alternative mechanisms of action for heparin-derived products. The company aims to obtain new pharmaceutical products that enable the regular administration of formulations that are administered daily in chronic and prolonged treatments. Its two segments are Manufacturing and Marketing.
81GF Score

Get the complete analysis for MEX:ROVIN

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN1,168.82
Price
MXN1,103.32
GF Value